论文部分内容阅读
2013年7月国际动脉粥样硬化学会(IAS)发表了“IAS立场报告:全球血脂异常诊疗建议”~([1])该建议汇集全世界不同地区15名国际知名专家参与制定,专家组主席为Scott M.Grundy教授。Scott M.Grundy教授是IAS主席,也是ATPⅡ指南第一作者和ATPⅢ指南编写委员会主席。建议汇总分析了ATPⅢ发表以来血脂异常与动脉粥样硬化领域的新研究和新证据,有显著的创新性。2013IAS建议制定的核心目的:降低新发动脉粥样硬化心血管疾病(ASCVD)发生风险,强调一级预防的目的是防止ASCVD。这些疾病包括冠心病
July 2013 The International Society of Atherosclerosis (IAS) published “IAS Position Report: Recommendations for Global Dyslipidemia Treatment” ~ ([1]) This proposal brings together 15 internationally recognized experts from different regions of the world The group chair is Professor Scott M. Grundy. Professor Scott M. Grundy is chair of IAS and is also the lead author of ATP II guide and the chairman of ATP III Guidelines Writing Committee. The recommendations summarize the new research and new evidence in the field of dyslipidemia and atherosclerosis since ATP III was published, with significant innovations. The core purpose of the 2013 IAS recommendations is to reduce the risk of new-onset atherosclerotic cardiovascular disease (ASCVD) and to emphasize that primary prevention is designed to prevent ASCVD. These diseases include coronary heart disease